Furthermore, a study involving pathway inhibition of gastric cancer cells has demonstrated a greater rate of gastric cancer cell death when inhibition of c-Met and the MEK-ERK pathway are combined, providing an additional potential combinatorial therapy to counter resistance to c-Met inhibition in melanoma [215]. This evidence concerns the gene MAP2K7 and gastric cancer.